Toronto Dominion Bank Grows Position in Gilead Sciences, Inc. (GILD)

Toronto Dominion Bank lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.6% during the 3rd quarter, HoldingsChannel reports. The firm owned 517,768 shares of the biopharmaceutical company’s stock after acquiring an additional 45,191 shares during the period. Toronto Dominion Bank’s holdings in Gilead Sciences were worth $41,946,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. BlackRock Inc. boosted its position in shares of Gilead Sciences by 1.9% during the second quarter. BlackRock Inc. now owns 104,906,494 shares of the biopharmaceutical company’s stock valued at $7,425,281,000 after purchasing an additional 1,937,031 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Gilead Sciences by 2.4% during the second quarter. Vanguard Group Inc. now owns 92,841,960 shares of the biopharmaceutical company’s stock valued at $6,571,355,000 after purchasing an additional 2,148,697 shares in the last quarter. Bank of New York Mellon Corp boosted its position in shares of Gilead Sciences by 1.0% during the second quarter. Bank of New York Mellon Corp now owns 30,881,405 shares of the biopharmaceutical company’s stock valued at $2,185,784,000 after purchasing an additional 310,607 shares in the last quarter. FMR LLC boosted its position in shares of Gilead Sciences by 1.1% during the second quarter. FMR LLC now owns 23,037,303 shares of the biopharmaceutical company’s stock valued at $1,630,581,000 after purchasing an additional 258,005 shares in the last quarter. Finally, Northern Trust Corp boosted its position in shares of Gilead Sciences by 0.7% during the second quarter. Northern Trust Corp now owns 16,430,476 shares of the biopharmaceutical company’s stock valued at $1,162,949,000 after purchasing an additional 116,780 shares in the last quarter. Institutional investors own 75.94% of the company’s stock.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of the business’s stock in a transaction dated Wednesday, November 1st. The stock was sold at an average price of $75.13, for a total transaction of $5,509,508.29. Following the completion of the sale, the insider now owns 3,070,099 shares of the company’s stock, valued at $230,656,537.87. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider John F. Milligan sold 220,000 shares of the business’s stock in a transaction dated Monday, November 13th. The shares were sold at an average price of $72.88, for a total value of $16,033,600.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 461,666 shares of company stock valued at $34,072,567. 1.30% of the stock is owned by company insiders.

Gilead Sciences, Inc. (NASDAQ GILD) opened at $79.02 on Friday. Gilead Sciences, Inc. has a one year low of $63.76 and a one year high of $86.27. The company has a quick ratio of 3.56, a current ratio of 3.68 and a debt-to-equity ratio of 1.10. The firm has a market capitalization of $103,190.00, a price-to-earnings ratio of 8.99, a PEG ratio of -1.58 and a beta of 1.13.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, October 26th. The biopharmaceutical company reported $2.27 EPS for the quarter, beating analysts’ consensus estimates of $2.13 by $0.14. The company had revenue of $6.51 billion during the quarter, compared to analysts’ expectations of $6.40 billion. Gilead Sciences had a return on equity of 57.15% and a net margin of 42.22%. Gilead Sciences’s revenue for the quarter was down 13.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.75 earnings per share. research analysts expect that Gilead Sciences, Inc. will post 8.53 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 28th. Investors of record on Friday, December 15th were given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.63%. The ex-dividend date was Thursday, December 14th. Gilead Sciences’s dividend payout ratio (DPR) is presently 23.66%.

Several research firms recently weighed in on GILD. BidaskClub lowered Gilead Sciences from a “hold” rating to a “sell” rating in a research report on Tuesday. Leerink Swann lifted their price target on Gilead Sciences from $84.00 to $85.00 and gave the company a “market perform” rating in a research report on Thursday, October 19th. Maxim Group restated a “hold” rating on shares of Gilead Sciences in a research report on Thursday, October 19th. Mizuho lifted their price target on Gilead Sciences from $77.00 to $83.00 and gave the company a “buy” rating in a research report on Wednesday, November 8th. Finally, CIBC assumed coverage on Gilead Sciences in a research note on Thursday, October 5th. They set a “market perform” rating for the company. Two research analysts have rated the stock with a sell rating, thirteen have issued a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $85.03.

COPYRIGHT VIOLATION WARNING: “Toronto Dominion Bank Grows Position in Gilead Sciences, Inc. (GILD)” was published by Stock Observer and is owned by of Stock Observer. If you are reading this report on another publication, it was illegally stolen and reposted in violation of U.S. & international trademark and copyright law. The correct version of this report can be read at https://www.thestockobserver.com/2018/01/13/toronto-dominion-bank-grows-position-in-gilead-sciences-inc-gild.html.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply